Amiodaronc Effect on Defibrillation Energy Requirement. Introdtiction: The effect of oral uiniodurone therapy on delibrillaliun energj requirements in patients with an implantable defibrillator has not heen estahlished.
Introduction
Amitxlarone i.s commonly prescribed for patients with an implantable defibrillator who receive frequent shocks for alrial or venlricular arrhythmias.'-' The effect of amiodarone on the defibrillation energy requirement is unclear. Indirect evidence suggests that amiodarone elevates monophasic detibriiiation energy requirements.^** However, a prospective comparison of detibriiiation energy requirements before and after chronic amicKlarone administration in piitients with an irnpkiniable detibrillator has not been reported. The purpo.se ot this study was to determine prospectively the effect of chronic amioda- rone therapy on the detibriiiation energy requirement in patients with an implantable detibriliator.
Methods

Patient Population
The study population consisted of 21 patients (19 men and 2 women, mean age 64 ± 15 years) with an implantable delibrillalur baving biphiisic wavct'itrms who were treated with amiodarone (Tiible I). Mean left ventricular ejection fraction was 0.31 ± 0.13. Coronary artery disease was present in 13 patients, nonischemic cardiomyopathy was present in 7 patients, and I patient bad no structural heart disease. The indication for implantable detibrillator placement was aborted sudden cardiac death in 8 patients, sustained ventricular tachycardia in 6. syncope in 4, and nonsustained ventricular tachycardia in 3. The indication for amiodarone therapy was atrial tibriliation in 13 patients and frequent symptomatic ventric- 
Defibrillation Energy Requirement Determinations
In tbe study patients, the defibrillation energy requirement was determined during ibe implantation procedure, I to 2 days after implant, 2 months later, and 2 months after amiodarone therapy was initiated. Tbe most recently determined defibrillation energy requirement before tbe initiation of amiodarone was defined as the baseline defibrillation energy requirement. The mean time between defibrillator implantation and baseline defibrillation energy requirement determination was 409 ± 450 days. The mean time interval between the baseline defibrillation energy requirement and initiation of amiodarone therapy was 211 ± 212 days.
At eacb defibrillaiion energy requirement determination, a slcp-down protocol was used (15. 10, 8, 6. 4, 3. 2, and I J). After ventricular tibrillation was induced using 60-Hz pacing, tbe impiantable defibrillator sensed, charged, and delivered the defibrillation shock. If normal rhythm was restored with the first shock, then the stepdown prottK'ol was continued until Ihe first sbock was ineffective. Wben tbe first shock failed during implantation testing, the programmed shock energy for the next ventricular fibrillation induction was 20 J. If ibe 20-J sbock failed, then a subcutaneous defibrillation electrode was added to the system, and the step-down protocol was repeated. At least 5 minutes elapsed between eacb ventricular fibrillation induction.
Amiodarone Administration
Tbe mean total dose of amiodarone before the amiodarone defibrillation energy requirement determination was 26.7 ± 1 l.l g. The mean total dose of amiodarone consisted of a mean amiodarone loading dose of 680 ± 166 mg/day for 12.6 ± 5.9 days, and a total mean loading dose of 9.1 ± 5.1 g. This was followed by a maintenance dose of amiodarone 276 ± 100 mg/day. Tbe total duration of amiodarone therapy before the amiodarone defibrillation energy requirement determination was 73 ± 21 days.
At tbe time of defibrillation energy requirement determination 2 months after the initiation of amiodarone tberapy, a venous blood sample was obtained and the serum amiodarone and desethylaniitxlitrone concentratiotis determined using high-performance liquid chromatography.
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Statistical Attalysis
Continuous variables are expressed as mean ± 1 SD and were compared using a paired or unpaired Mest, as appropriate. Regression analysis was used to assess a relaiionsliip between two continuous variables. Stepwise regression analysis was used to test for independence between variables. A Chi-square or Fisher's exact test was used to compare nominal variables. P < 0.05 was considered statistically significant.
Results
The baseline defibrillation energy requirement was 9.4 ± 4.6 J and the defibriliation energy requirement after amiodarone therapy was 13.7 ± 5,6 J (P = 0.01; Fig. 1 ). The defibrillation energy requirement increased by 4.0 ± 5.3 J or 62% ± 74%. The shocking resistance before (47 ± 12 O) and after amiodarone therapy (46 ± 7 li) did not change .significantly (P = 0.8).
The mean amiodarone. desethylamiodarone, and combined amiodarone-desethylainiodarone concentrations were I.I ± 0.56 mg/dL. 1.0 ± 0.44 mg/dL. and 2.1 ± 0.96 mg/dL, respectively. There was a linear relationship between the serum amiodarone concentration and the detibrillation energy requirement (r = 0.6, P = 0.02). tbe change in defibrillation energy requirement (r ^ 0.8. P = 0.001), and the percent change in deftbrillation energy requirement (r ^ 0.7, P = 0.004; Fig. 2 ). The serum desethylamiodarone concentration also demon.strated a linear relationship with the defibrillation energy requirement (r = 0.6, P = 0.02), change in tbe defibrillation energy requirement (r = 0.8, P = 0.002), and percent change in the defibrillation energy requirement (r = 0.7, P = 0.003; Fig. 3 ). Additionally, a linear relationship was observed between the combined amiodarone-desethylamiodarone concentrations and the defibrillation energy requirement (r = 0.6, P = 0,01), cbange in the detibrillation energy requirement (r = 0.7, P = 0.002), and percent change in defibrillation energy requirement (r = 0.7, P = 0.002; Fig. 4) . Stepwise regression analysis of amiodarone, desethylamiodarone, and combined amiodarone-desethvlamiodarone concentrations demonstrated that only the combined concentrations of amiodarone and desethylamiodarone were independently associated with the defibriilation energy requirement.
Tbere was no relationship between the defibriliation energy requirement and tbe daily amiodarone dose (P = 0.6), duration of amiodarone therapy (P -0.2), total dose of amiodarone (P = 0,1), or interval between the defibrillation energy requirement determinations (P = 0.4). No clinical characteristics, including age, gender, ejection fraction, type of heart disease, or indication for implantable defibrillator therapy, correlated with the defibrillation energy requirement, change in defibrillation energy requirement, or percent change in the defibrillation energy requirement.
Discussion
Major Findings
The results of this prospective study demonstrate that chronic amiodarone therapy increases the defibrillation energy requirement by approximately 60%. Furthermore, the combined serum concentrations of amiodarone and desethylamiodarone independently correlate with the defibrillation energy requirement after initiation of amio- darone therapy in patients with an implantable defibrillator.
Mechanism
The mechanism of amiodarone's effects on the defibrillation energy requirement is unclear, perhaps because the mechanism of successful detibrillation is controversial. Some investigators proposed tbat a defibrillation shock must be of sufficient energy to depolarize tbe myocardium in varying states of refractoriness.'' Tbis results in uniform ventricular refractoriness and termination of tbe fibrillation. Amiodarone and its metabolite desetbylamiodarone increase action potential duration by blocking potassium channels.'"" Amiodarone's Class III effects may increase the volume of refractory myocardium, tbcrcby necessitating a stronger shock for succes.sful defibrillation.
Previous Studies
This is the first published .study to compare the defibrillation energy requirement before and after tbe initiation of oral amiodarone therapy. The present study evaluated tiiis relationship only with biphasic defibrillation.
Tbis is also tbe first published study to demonstrate that the amiodarone and desetbylamiodarone concentrations correlate witb tbe biphasic defibrillation energy requirement.
Only one previous study evaluated the relation.ship between amiodarone and desethylamiodarone concentrations and the defibrillation energy requirement.** In tbat study, amiodarone therapy correlated with an increased monophasic defibriilation energy requirement and a bigher frequency of a subcutaneous defibrillation electrode use.^ However, tbe drug concentration did not correlate with defibrillation efficacy.^ Tbe difference between tbat previous study and the present study may be due to different effects of amiodarone on bipbasic and monophasic defibrillation.
Limitatiotis
Tbe major limitation of this study is the small sample size. Second, this study did not control for tbe effect of time on the defibrillation energy requirement. The mean time lrom defibrillator implantation to tbe study's baseline detibrillation requirement determination was 4(X) days. If bipbasic defibrillation efficacy cbanges over time, it occurs witbin 2 months of implantation and then probably remains stable over at least 2 years.'^"''' 
Clinical Implications
The results of this study suggest that the defihrillation energy requirement .should he determined 2 to 3 months after amiodarone therapy is initiated in patients with an implantahle defibrillator. This may he especially important for patients in whom increases in the defibrillation energy requirement may compromise the defibrillator safety margin.
